FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

108 letters match. Newest first.

  1. Remedy Meds

    FDA warns Remedy Meds that its telehealth site misleadingly labels pharmacy-made semaglutide and tirzepatide with approved-drug comparisons.

    Low
  2. EA WORKS Limited Liability Company dba Trust Labs

    FDA warned Trust Labs it sold unapproved compounded retatrutide and made false FDA-approval claims for semaglutide and tirzepatide online.

    High risk
  3. Fancy Meds, LLC dba Fancy Meds

    FDA warns Fancy Meds that its compounded semaglutide and tirzepatide website claims are false or misleading.

    Low
  4. Matthew Stern, CEO MyStart Health LLC.

    FDA warns MyStart Health over 'Generic Ozempic' claims for compounded semaglutide.

    Low
  5. Elite Health Center

    FDA warned Elite Health Center that its website falsely implied compounded semaglutide was FDA-approved, making the drugs misbranded.

    Low
  6. Curex

    FDA warned Curex that its website ads for compounded semaglutide and tirzepatide are false or misleading.

    High risk
  7. Healthon Inc. dba Healthon

    FDA warned Healthon over unapproved compounded semaglutide and tirzepatide sold online with false 'FDA-approved' and 'same as' claims.

    High risk
  8. ProRx, LLC

    FDA warns ProRx, LLC about insanitary sterile compounded-drug production and manufacturing-quality failures.

    High risk